• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Importance The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant
patients without a prior cardiovascular event (primary prevention) have not been fully …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …

Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …

Convergent experimental and clinical evidence have established the pathophysiological
importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in …

Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …

Background Statins reduce LDL cholesterol and cardiovascular events among those with or
without diabetes but have been reported to increase new-onset diabetes. The CLEAR …